Literature DB >> 16635656

Large or multiple congenital melanocytic nevi: occurrence of neurocutaneous melanocytosis in 1008 persons.

Bari Joan Bett1.   

Abstract

BACKGROUND: There is a dearth of information regarding the occurrence of neurocutaneous melanocytosis (NCM) in a large cohort of persons with large congenital melanocytic nevi (LMCN) or multiple congenital melanocytic nevi (MCMN).
OBJECTIVE: The purpose of this article is to report occurrence of NCM and other complications in 1008 persons having LCMN or MCMN.
METHODS: Evaluation of information obtained from a database of persons with LCMN or MCMN voluntarily submitted by the affected persons to a nevus support group, the Nevus Network.
RESULTS: Of those with truncal LCMN, 6.8% developed significant complications, 4.8% developed symptomatic NCM, and 2.3% died from either benign or malignant NCM or cutaneous melanoma. Of the 4.8% of persons with a truncal nevus who developed symptomatic NCM, 34% died. Of those with head or extremity LCMN, 0.8% developed symptomatic NCM, and, to date, none have died from any cause. Of the small number with MCMN without a giant nevus, 71% developed symptomatic NCM, and 41% died of it. LIMITATIONS: Attending physician confirmation of submitted information was unavailable.
CONCLUSIONS: LCMN of the trunk were associated with a relatively low occurrence of medical complications and death in our group, considering the large nevomelanocytic burden present. If symptomatic NCM developed in those with truncal nevi, the occurrence of death rose to a third. LCMN of the head or extremity were associated with minimal medical complications and no deaths. In contrast, most of the rare persons (N = 17) with MCMN developed symptomatic NCM, and more than a third died.

Entities:  

Mesh:

Year:  2006        PMID: 16635656     DOI: 10.1016/j.jaad.2005.10.040

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

Review 1.  [New aspects of congenital melanocytic nevi].

Authors:  S Krengel
Journal:  Hautarzt       Date:  2012-02       Impact factor: 0.751

2.  NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.

Authors:  Christelle Charbel; Romain H Fontaine; Gabriel G Malouf; Arnaud Picard; Natacha Kadlub; Nizar El-Murr; Alexandre How-Kit; Xiaoping Su; Aurore Coulomb-L'Hermine; Jorg Tost; Samia Mourah; Selim Aractingi; Sarah Guégan
Journal:  J Invest Dermatol       Date:  2013-10-15       Impact factor: 8.551

3.  Neurocutaneous melanocytosis (melanosis).

Authors:  Martino Ruggieri; Agata Polizzi; Stefano Catanzaro; Manuela Lo Bianco; Andrea D Praticò; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2020-10-13       Impact factor: 1.475

4.  [Congenital nevi in childhood].

Authors:  R Wälchli; M Theiler; K Neuhaus; L Weibel
Journal:  Hautarzt       Date:  2013-01       Impact factor: 0.751

5.  [Therapy of congenital melanocytic nevi. Excision, dermabrasion, laser].

Authors:  B Konz
Journal:  Hautarzt       Date:  2007-08       Impact factor: 0.751

6.  Transcriptome Analysis of Large to Giant Congenital Melanocytic Nevus Reveals Cell Cycle Arrest and Immune Evasion: Identifying Potential Targets for Treatment.

Authors:  Boxuan Wei; Jieyu Gu; Ran Duan; Bowen Gao; Min Wu; Shengliang Zhou; Xiaolu Huang; Feng Xie
Journal:  J Immunol Res       Date:  2021-12-06       Impact factor: 4.818

Review 7.  Neurological signs, symptoms and MRI abnormalities in patients with congenital melanocytic naevi and evaluation of routine MRI-screening: systematic review and meta-analysis.

Authors:  Anne C Fledderus; Anna Linn Widdershoven; Oren Lapid; Corstiaan C Breugem; Suzanne G M A Pasmans; Chantal M A M van der Horst; Marc M Engelen; Phyllis I Spuls
Journal:  Orphanet J Rare Dis       Date:  2022-03-02       Impact factor: 4.123

Review 8.  Giant congenital melanocytic nevus.

Authors:  Ana Carolina Leite Viana; Bernardo Gontijo; Flávia Vasques Bittencourt
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.